期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 62, 期 12, 页码 1156-1166出版社
ELSEVIER
DOI: 10.1016/j.addr.2010.08.010
关键词
Stroma; Cellular reprogramming; Trophic factor; Immunomodulation; Delivery vehicle
资金
- NHLBI NIH HHS [R01 HL070566, R01 HL097623, R01 HL073737] Funding Source: Medline
- NICHD NIH HHS [R01 HD043038] Funding Source: Medline
Mesenchymal stem cells (MSCs) possess a set of several fairly unique properties which make them ideally suited both for cellular therapies/regenerative medicine, and as vehicles for gene and drug delivery. These include: 1) relative ease of isolation; 2) the ability to differentiate into a wide variety of seemingly functional cell types of both mesenchymal and non-mesenchymal origin; 3) the ability to be extensively expanded in culture without a loss of differentiative capacity; 4) they are not only hypoimmunogenic, but they produce immunosuppression upon transplantation; 5) their pronounced anti-inflammatory properties; and 6) their ability to home to damaged tissues, tumors, and metastases following in vivo administration. In this review, we summarize the latest research in the use of mesenchymal stem cells in regenerative medicine, as immunomodulatory/anti-inflammatory agents, and as vehicles for transferring both therapeutic genes in genetic disease and genes designed to destroy malignant cells. (c) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据